Moderna’s third quarter proves COVID can still prove a viable source of revenue. | Moderna posted $1.3 billion in third quarter revenue, vastly surpassing analyst estimates and avoiding a predicted ...

The team at Evercore ISI, for its part, claimed Rasonque’s debut was nothing short of “eye-popping.” The shop is now looking at a potential $500 million in Rasonque sales for the year’s final quarter, ...

AstraZeneca may not need a major acquisition to sustain growth beyond 2030—but the British pharma is reportedly not stopping ...

ANI Pharmaceuticals is forking over more than half a billion dollars to broaden its rare disease business. | ANI ...

Alnylam Pharmaceuticals is seeking a new chief commercial officer as the biopharma announced that its six-year CCO veteran ...

Knudsen’s departure will mark the end of a 27-year run at Novo, with Doustdar telling analysts Wednesday that the outgoing ...

Amid surging sales of Rezdiffra, Madrigal Pharmaceuticals is facing a whistleblower lawsuit alleging that senior leadership ...

Vanda Pharmaceuticals’ action-packed TV ad for motion-sickness drug Nereus has irked the FDA, which accused (PDF) the company ...

Merck & Co. is chasing the finish line with its eye on one prize: a world without cancer. | In “From Our Pipeline to the ...

Would you know the difference between a normal cold and one that has turned into something more serious? | Would you know the ...

VintaBio, which debuted in 2023 as a CDMO focused on cranking out viral vectors for cell and gene therapy production, is having its manufacturing facility and intellectual property ...

Samsung Biologics' labor union has another strike in the works after action planned for last month was held up by an ...